BioVisioN AG Sells Its Subsidiary ImVisioN GmbH to Nextech Venture, L.P.HANOVER, Germany -- German biotech company BioVisioN AG has sold its spin-off, ImVisioN GmbH, to the Swiss based life science investment firm Nextech Venture, L.P. ImVisioN focuses on the development of novel immunotherapeutics based on its proprietary MAT (Modular-Antigen-Transport) technology to treat allergic diseases, (chronic) infectious diseases and possibly cancer. The technology was developed by BioVisioN together with its partner the Swiss Institute of Allergy and Asthma Research Swiss Institute of Allergy and Asthma Research (SIAF), founded in 1986, is performing basic research in the field of allergy and asthma with the aim to improve understanding and therapy of this disease, which affects around 30-40% of the westernized population. (SIAF SIAF Shareware Industry Awards Foundation SIAF Submissive Introverted Abstract Feeler (Jung personality type indicator) SIAF Sistema Administrativo y Financiero (Guatemala) SIAF Small Independent Action Force ). This new immunization immunization: see immunity; vaccination. concept is based on an improved antigen presentation within the immune system. The company's lead product, IVN IVN Interactive Video Network IVN Intravenous IVN Internationale Vereniging voor Neerlandistiek IVN Intravenous Nutrition IVN Integrated Voice Network IVN Intervening Networks IVN in Vehicle Network 201, an immunotherapeutic to treat cat dander dander /dan·der/ (dan´der) small scales from the hair or feathers of animals, which may be a cause of allergy in sensitive persons. dan·der n. allergy is currently undergoing late preclinical development and is expected to enter clinical trials early 2006. Nextech Venture's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and founding partner, Dr. Alfred Scheidegger, emphasizes the importance of ImVisioN: "Only innovative drugs can answer our society health needs and only they can provide risk-taking investors with attractive returns in early stage life science. It will be ImVisioN's challenge to fully exploit the potential of MAT - developing a portfolio of innovative drugs that cannot only change the way we treat allergy but even the way we immunize im·mu·nize v. 1. To render immune. 2. To produce immunity in, as by inoculation. im . If MAT works, we will see the next blockbuster here!" BioVisioN's Chief Business Officer Dr. Rainer Voegeli points out that the ImVisioN spin-off is a part of BioVisioN's business model: "As a Biological Research Organization BioVisioN offers mainly services for peptide biomarker discovery but pursues also selected in-house research projects. It is the policy of BioVisioN to partner or to sell projects which have reached development status. ImVisioN is the first, others will follow." About BioVisioN AG BioVisioN AG specializes in the identification of disease-relevant peptides and proteins using its proprietary Peptidomics(R) technologies in order to discover new diagnostic markers, or biomarkers and therapeutic leads and targets. Apart from research collaborations, BioVisioN provides access to its technology also in fee-for-service contracts as a Biological Research Organization. For further information please visit www.peptidomics.com. About Nextech Venture, L.P. Nextech Venture, L.P., was founded in 1999 and has CHF CHF In currencies, this is the abbreviation for the Swiss Franc. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 70 million under management. Nextech Venture invests in selected life science companies in Europe and builds up successful business ventures from innovations originating in academia and industry in life science. For further information please visit www.nextechventure.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion